Characterization of human cytochrome P450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine

Drug Metabolism and Disposition

Volumn 34, Issue 3, 2006, Pages 471-476

  Wójcikowski, Jacek ^a   Maurel, Patrick ^b,c   Daniel, Władysława A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; MESORIDAZINE; N DEMETHYLASE; NEUROLEPTIC AGENT; PERAZINE; PHENOTHIAZINE; PIPERIDINE DERIVATIVE; PROMAZINE; SULFORIDAZINE; SULFOXIDE; THIORIDAZINE;

ARTICLE; CARDIOTOXICITY; CATALYSIS; DEMETHYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SULFOXIDATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; CATALYSIS; CLONING, MOLECULAR; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INSECTS; MICROSOMES, LIVER; PIPERIDINES; THIORIDAZINE;

EID: 33344460427     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.105.006445     Document Type: Article

References (25)

1. Axelsson R (1977) On the serum concentrations and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine side-chain sulfone in chronic psychotic patients. Curr Ther Res Clin Exp 21:587-605.
2. Berecz R, De La Rubia A, Dorado P, Fernandez-Salguero P, Dahl M-L, and Llerena A (2003) Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 59:45-50.
3. Bylund DB (1981) Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors. J Pharmacol Exp Ther 217:81-86.
4. Cohen BM, Lipiński JF, and Waternaux C (1989) A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacology 97:481-488.
5. Daniel WA, Syrek M, Haduch A, and Wójcikowski J (1999) The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. Exp Toxicol Pathol 51:309-314.
6. Daniel WA, Syrek M, Haduch A, and Wójcikowski J (2000) Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants. Br J Pharmacol 131:287-295.
7. Daniel WA, Syrek M, Mach A, Wójcikowski J, and Boksa J (1997) Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment. Pol J Pharmacol 49:439-452.
8. Gottschalk LA, Dinovo E, Biener R, and Nandi BR (1978) Plasma concentrations of thioridazine metabolites and ECG abnormalities. J Pharm Sci 67:155-157.
9. Hale PW Jr and Poklis A (1986) Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol Appl Pharmacol 86:44-55.
10. Heiman EM (1977) Cardiac toxicity with thioridazine-tricyclic antidepressant combination. J Nerv Ment Dis 165:139-143.
11. Hustert E, Zibat A, Prescan-Siedel E, Eiselt R, Mueller R, Fub C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, et al. (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454-1459.
12. Hyttel J, Larsen JJ, Christensen AV, and Amt J (1985) Receptor binding profiles of neuroleptics, in Dyskinesia - Research and Treatment (Casey DE, Chase TN, Christensen AV, and Gerlach J eds) pp 9-18, Springer, Berlin.
13. Lewis DFV (2001) Substrate selectivity and metabolism, in Cytochromes P450. Structures and Function, pp 76-117, Taylor and Francis, London.
14. Lin G, Hawes EM, Mckay G, Korchinski ED, and Midha KK (1993) Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat. Xenobiotica 23:1095-1074.
15. Llerena A, Berecz R, De La Rubia A, and Dorado P (2002) QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol 16:361-364.
16. Llerena A, Berecz R, De La Rubia A, Fernandez-Salguero P, and Dorado P (2001) Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 23:616-620.
17. Llerena A, Berecz R, De La Rubia A, Norberto MJ, and Benitez J (2000) Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit 22:397-401.
18. Meyer J, Woggon B, Baumann P, and Meyer UA (1990) Clinical implications of slow sulphoxidation of thioridazine in poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 39:613-614.
19. Papadopoulos AS, Crammer JL, and Cowan DA (1985) Phenolic metabolites of thioridazine in man. Xenobiotica 15:309-316.
20. Richelson E and Nelson A (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103:197-204.
21. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
22. Svendsen CN and Bird ED (1986) HPLC with electrochemical detection to measure chlorpromazine, thioridazine and metabolites in human brain. Psychopharmacology 90:316-321.
23. von Bahr C, Movin G, Nordin C, Liden A, Hammarlund-Udenaes M, Hedberg A, Ring H, and Sjögvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 49:234-240.
24. Wójcikowski J, Pichard-Garcia L, Maurel P, and Daniel WA (2003) Contribution of human cytochrome P-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol 138:1465-1474.
25. Wójcikowski J, Pichard-Garcia L, Maurel P, and Daniel WA (2004) The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol 14:199-208.